Literature DB >> 17158750

Androgen receptor corepressors and prostate cancer.

Craig J Burd1, Lisa M Morey, Karen E Knudsen.   

Abstract

The androgen receptor (AR) mediates the effects of male steroid hormones (androgens) and contributes to a wide variety of physiological and pathophysiological conditions. As such, the regulatory mechanisms governing AR activity are of high significance. Concerted effort has been placed on delineating the mechanisms that control AR activity in prostate cancer, as AR is required for survival and proliferation in this tumor type. Moreover, AR is the central therapeutic target for metastatic prostate cancers, and recurrent tumors evade therapy by restoring AR activity. It is increasingly apparent that AR cofactors which modulate receptor activity can contribute to prostate cancer growth or progression, and this has been particularly well established for AR coactivators. The present review is focused on the role of AR corepressors in governing androgen action, with a specific emphasis on their activities in prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17158750     DOI: 10.1677/erc.1.01115

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  30 in total

1.  Activation of β-catenin signaling in androgen receptor-negative prostate cancer cells.

Authors:  Xinhai Wan; Jie Liu; Jing-Fang Lu; Vassiliki Tzelepi; Jun Yang; Michael W Starbuck; Lixia Diao; Jing Wang; Eleni Efstathiou; Elba S Vazquez; Patricia Troncoso; Sankar N Maity; Nora M Navone
Journal:  Clin Cancer Res       Date:  2012-02-01       Impact factor: 12.531

2.  A transcriptional repressor co-regulatory network governing androgen response in prostate cancers.

Authors:  Kern Rei Chng; Cheng Wei Chang; Si Kee Tan; Chong Yang; Shu Zhen Hong; Noel Yan Wei Sng; Edwin Cheung
Journal:  EMBO J       Date:  2012-04-24       Impact factor: 11.598

3.  Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer.

Authors:  Karen E Knudsen; William Kevin Kelly
Journal:  Expert Rev Endocrinol Metab       Date:  2011-05

4.  Rational design of substrate-based multivalent inhibitors of the histone acetyltransferase Tip60.

Authors:  Chao Yang; Liza Ngo; Y George Zheng
Journal:  ChemMedChem       Date:  2014-01-20       Impact factor: 3.466

5.  Reconfiguring the AR-TIF2 Protein-Protein Interaction HCS Assay in Prostate Cancer Cells and Characterizing the Hits from a LOPAC Screen.

Authors:  Ashley T Fancher; Yun Hua; Daniel P Camarco; David A Close; Christopher J Strock; Paul A Johnston
Journal:  Assay Drug Dev Technol       Date:  2016-09-08       Impact factor: 1.738

6.  High-content positional biosensor screening assay for compounds to prevent or disrupt androgen receptor and transcriptional intermediary factor 2 protein-protein interactions.

Authors:  Yun Hua; Tong Ying Shun; Christopher J Strock; Paul A Johnston
Journal:  Assay Drug Dev Technol       Date:  2014-09       Impact factor: 1.738

7.  DHT selectively reverses Smad3-mediated/TGF-beta-induced responses through transcriptional down-regulation of Smad3 in prostate epithelial cells.

Authors:  Kyung Song; Hui Wang; Tracy L Krebs; Bingcheng Wang; Thomas J Kelley; David Danielpour
Journal:  Mol Endocrinol       Date:  2010-08-25

8.  Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes.

Authors:  Michael A Augello; Craig J Burd; Ruth Birbe; Christopher McNair; Adam Ertel; Michael S Magee; Daniel E Frigo; Kari Wilder-Romans; Mark Shilkrut; Sumin Han; Danielle L Jernigan; Jeffry L Dean; Alessandro Fatatis; Donald P McDonnell; Tapio Visakorpi; Felix Y Feng; Karen E Knudsen
Journal:  J Clin Invest       Date:  2012-12-21       Impact factor: 14.808

9.  Androgenic control of transforming growth factor-beta signaling in prostate epithelial cells through transcriptional suppression of transforming growth factor-beta receptor II.

Authors:  Kyung Song; Hui Wang; Tracy L Krebs; Seong-Jin Kim; David Danielpour
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

10.  ARF represses androgen receptor transactivation in prostate cancer.

Authors:  Wenfu Lu; Yingqiu Xie; Yufang Ma; Robert J Matusik; Zhenbang Chen
Journal:  Mol Endocrinol       Date:  2013-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.